Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,680 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy.
Elliott JH, Wightman F, Solomon A, Ghneim K, Ahlers J, Cameron MJ, Smith MZ, Spelman T, McMahon J, Velayudham P, Brown G, Roney J, Watson J, Prince MH, Hoy JF, Chomont N, Fromentin R, Procopio FA, Zeidan J, Palmer S, Odevall L, Johnstone RW, Martin BP, Sinclair E, Deeks SG, Hazuda DJ, Cameron PU, Sékaly RP, Lewin SR. Elliott JH, et al. Among authors: palmer s. PLoS Pathog. 2014 Nov 13;10(10):e1004473. doi: 10.1371/journal.ppat.1004473. eCollection 2014 Oct. PLoS Pathog. 2014. PMID: 25393648 Free PMC article. Clinical Trial.
ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia.
Maldarelli F, Palmer S, King MS, Wiegand A, Polis MA, Mican J, Kovacs JA, Davey RT, Rock-Kress D, Dewar R, Liu S, Metcalf JA, Rehm C, Brun SC, Hanna GJ, Kempf DJ, Coffin JM, Mellors JW. Maldarelli F, et al. Among authors: palmer s. PLoS Pathog. 2007 Apr;3(4):e46. doi: 10.1371/journal.ppat.0030046. PLoS Pathog. 2007. PMID: 17411338 Free PMC article. Clinical Trial.
Detection of nonnucleoside reverse-transcriptase inhibitor-resistant HIV-1 after discontinuation of virologically suppressive antiretroviral therapy.
Hare CB, Mellors J, Krambrink A, Su Z, Skiest D, Margolis DM, Patel SS, Barnas D, Frenkel L, Coombs RW, Aweeka F, Morse GD, Haas DW, Boltz V, Palmer S, Coffin J, Havlir DV. Hare CB, et al. Among authors: palmer s. Clin Infect Dis. 2008 Aug 1;47(3):421-4. doi: 10.1086/589867. Clin Infect Dis. 2008. PMID: 18558886 Free PMC article. Clinical Trial.
Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy.
McMahon D, Jones J, Wiegand A, Gange SJ, Kearney M, Palmer S, McNulty S, Metcalf JA, Acosta E, Rehm C, Coffin JM, Mellors JW, Maldarelli F. McMahon D, et al. Among authors: palmer s. Clin Infect Dis. 2010 Mar 15;50(6):912-9. doi: 10.1086/650749. Clin Infect Dis. 2010. PMID: 20156060 Free PMC article.
The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial.
Gandhi RT, Zheng L, Bosch RJ, Chan ES, Margolis DM, Read S, Kallungal B, Palmer S, Medvik K, Lederman MM, Alatrakchi N, Jacobson JM, Wiegand A, Kearney M, Coffin JM, Mellors JW, Eron JJ; AIDS Clinical Trials Group A5244 team. Gandhi RT, et al. Among authors: palmer s. PLoS Med. 2010 Aug 10;7(8):e1000321. doi: 10.1371/journal.pmed.1000321. PLoS Med. 2010. PMID: 20711481 Free PMC article. Clinical Trial.
A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response.
Hatano H, Hayes TL, Dahl V, Sinclair E, Lee TH, Hoh R, Lampiris H, Hunt PW, Palmer S, McCune JM, Martin JN, Busch MP, Shacklett BL, Deeks SG. Hatano H, et al. Among authors: palmer s. J Infect Dis. 2011 Apr 1;203(7):960-8. doi: 10.1093/infdis/jiq138. J Infect Dis. 2011. PMID: 21402547 Free PMC article. Clinical Trial.
No effect of raltegravir intensification on viral replication markers in the blood of HIV-1-infected patients receiving antiretroviral therapy.
Gandhi RT, Coombs RW, Chan ES, Bosch RJ, Zheng L, Margolis DM, Read S, Kallungal B, Chang M, Goecker EA, Wiegand A, Kearney M, Jacobson JM, D'Aquila R, Lederman MM, Mellors JW, Eron JJ; AIDS Clinical Trials Group (ACTG) A5244 Team. Gandhi RT, et al. J Acquir Immune Defic Syndr. 2012 Mar 1;59(3):229-35. doi: 10.1097/QAI.0b013e31823fd1f2. J Acquir Immune Defic Syndr. 2012. PMID: 22083073 Free PMC article. Clinical Trial.
Intensification of antiretroviral therapy with a CCR5 antagonist in patients with chronic HIV-1 infection: effect on T cells latently infected.
Gutiérrez C, Díaz L, Vallejo A, Hernández-Novoa B, Abad M, Madrid N, Dahl V, Rubio R, Moreno AM, Dronda F, Casado JL, Navas E, Pérez-Elías MJ, Zamora J, Palmer S, Muñoz E, Muñoz-Fernández MÁ, Moreno S. Gutiérrez C, et al. Among authors: palmer s. PLoS One. 2011;6(12):e27864. doi: 10.1371/journal.pone.0027864. Epub 2011 Dec 8. PLoS One. 2011. PMID: 22174752 Free PMC article. Clinical Trial.
2,680 results